What Happened

On Sept 21, 2026, Novo Nordisk CEO Mike Maziar Doustdar disclosed at the company's Capital Markets Day that total workforce departures over the past year have reached 13,000. This includes 9,000 previously announced layoffs from a September 2025 restructuring plus 4,000 additional departures attributed to normal attrition, retirements, voluntary exits, and unfilled roles. The company's headcount now sits at 67,000, down from a peak of 78,000 in 2025.

Doustdar stated that the reductions are “necessary” and part of a strategy to redirect funds toward R&D and enhance competitiveness.

Who Is Affected

All 13,000 departures represent roles across Novo Nordisk's global operations, though the company declined to specify geographic or functional breakdowns. The cuts impact R&D, commercial, and support functions as Novo consolidates resources. The CEO emphasized that the workforce reduction is part of a broader transformation to unify the organization and invest in pipeline areas including obesity, diabetes, liver diseases, cardiovascular conditions, and blood/endocrine disorders.

Market Impact

• Novo Nordisk's stock fell nearly 8% on Sept 21 to $39.80, reflecting investor skepticism about the restructuring's pace and the company's ability to regain leadership in the weight-loss market.
• CEO Doustdar acknowledged erosion of Novo's competitive position against rival Eli Lilly, particularly in GLP-1 obesity treatments.
• The company aims to hit $23 billion in revenue by 2035, but investors remain unconvinced given pipeline setbacks and declining sales.

What to Watch

As Novo redirects cost savings into R&D, watch for new pipeline announcements and clinical trial outcomes in obesity, diabetes, and liver disease. The company's hiring patterns and vendor relationships may shift as it prioritizes research over general headcount. SDRs should monitor Novo's procurement of R&D productivity tools, clinical data platforms, and change-management consulting services.

Related coverage

• ArsenalBio sheds most of staff in pivot to in vivo CAR-T
• TRex Bio and Retension Pharmaceuticals file for IPO; ADARx eyes up to $446M listing
• H1 Partners with Novo Nordisk for AI-Driven Clinical Development
• TScan axes 75% of workforce, prioritizes solid tumor program